vs
Side-by-side financial comparison of BGSF, INC. (BGSF) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
BGSF, INC. is the larger business by last-quarter revenue ($22.0M vs $13.7M, roughly 1.6× Xilio Therapeutics, Inc.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs -5.3%, a 81.0% gap on every dollar of revenue. BGSF, INC. produced more free cash flow last quarter ($1.7M vs $-2.1M).
BGSF Inc. is a leading U.S.-headquartered workforce solutions firm that provides tailored staffing, talent recruitment, and end-to-end workforce management services. It serves core segments including information technology, healthcare, professional administration, light industrial, and creative industries, catering to small, mid-sized and large enterprise clients across North America.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
BGSF vs XLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $22.0M | $13.7M |
| Net Profit | $-1.2M | $10.4M |
| Gross Margin | 35.0% | — |
| Operating Margin | -17.6% | -86.5% |
| Net Margin | -5.3% | 75.7% |
| Revenue YoY | -9.4% | — |
| Net Profit YoY | -18.2% | 179.1% |
| EPS (diluted) | $-0.12 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $22.0M | $13.7M | ||
| Q3 25 | $26.9M | $19.1M | ||
| Q2 25 | $23.5M | $8.1M | ||
| Q1 25 | $20.9M | $2.9M | ||
| Q4 24 | $24.3M | — | ||
| Q3 24 | $29.8M | — | ||
| Q2 24 | $25.7M | — | ||
| Q1 24 | $24.5M | — |
| Q4 25 | $-1.2M | $10.4M | ||
| Q3 25 | $-5.8M | $-16.3M | ||
| Q2 25 | $-3.7M | $-15.8M | ||
| Q1 25 | $-722.0K | $-13.3M | ||
| Q4 24 | $-981.0K | — | ||
| Q3 24 | $-804.0K | — | ||
| Q2 24 | $-761.0K | — | ||
| Q1 24 | $-792.0K | — |
| Q4 25 | 35.0% | — | ||
| Q3 25 | 35.9% | — | ||
| Q2 25 | 35.8% | — | ||
| Q1 25 | 36.2% | — | ||
| Q4 24 | 35.9% | — | ||
| Q3 24 | 35.9% | — | ||
| Q2 24 | 37.3% | — | ||
| Q1 24 | 38.1% | — |
| Q4 25 | -17.6% | -86.5% | ||
| Q3 25 | -3.5% | -10.1% | ||
| Q2 25 | -18.8% | -177.7% | ||
| Q1 25 | 1.6% | -472.7% | ||
| Q4 24 | -15.7% | — | ||
| Q3 24 | -3.4% | — | ||
| Q2 24 | -5.7% | — | ||
| Q1 24 | 1.7% | — |
| Q4 25 | -5.3% | 75.7% | ||
| Q3 25 | -21.6% | -85.4% | ||
| Q2 25 | -15.9% | -196.0% | ||
| Q1 25 | -3.5% | -452.7% | ||
| Q4 24 | -4.0% | — | ||
| Q3 24 | -2.7% | — | ||
| Q2 24 | -3.0% | — | ||
| Q1 24 | -3.2% | — |
| Q4 25 | $-0.12 | $-3.74 | ||
| Q3 25 | $-0.52 | $-0.11 | ||
| Q2 25 | $-0.34 | $-0.16 | ||
| Q1 25 | $-0.06 | $-0.18 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.07 | — | ||
| Q2 24 | $-0.07 | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $48.1M | $35.3M |
| Total Assets | $57.8M | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $137.5M | ||
| Q3 25 | $41.2M | $103.8M | ||
| Q2 25 | $2.8M | $121.6M | ||
| Q1 25 | $2.0M | $89.1M | ||
| Q4 24 | $32.0K | — | ||
| Q3 24 | $262 | — | ||
| Q2 24 | $226 | — | ||
| Q1 24 | $50 | — |
| Q4 25 | $48.1M | $35.3M | ||
| Q3 25 | $50.7M | $-8.1M | ||
| Q2 25 | $78.3M | $7.1M | ||
| Q1 25 | $81.8M | $10.7M | ||
| Q4 24 | $82.3M | — | ||
| Q3 24 | $82.9M | — | ||
| Q2 24 | $83.2M | — | ||
| Q1 24 | $83.6M | — |
| Q4 25 | $57.8M | $154.7M | ||
| Q3 25 | $83.6M | $133.7M | ||
| Q2 25 | $149.7M | $133.8M | ||
| Q1 25 | $152.3M | $103.7M | ||
| Q4 24 | $150.1M | — | ||
| Q3 24 | $157.3K | — | ||
| Q2 24 | $159.8K | — | ||
| Q1 24 | $170.6K | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.7M | $-2.0M |
| Free Cash FlowOCF − Capex | $1.7M | $-2.1M |
| FCF MarginFCF / Revenue | 7.6% | -15.3% |
| Capex IntensityCapex / Revenue | 0.1% | 0.7% |
| Cash ConversionOCF / Net Profit | — | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | $-16.0K | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.7M | $-2.0M | ||
| Q3 25 | $-4.8M | $-17.5M | ||
| Q2 25 | $2.2M | $-14.5M | ||
| Q1 25 | $1.1M | $29.0M | ||
| Q4 24 | $3.2M | — | ||
| Q3 24 | $6.5M | — | ||
| Q2 24 | $7.3M | — | ||
| Q1 24 | $7.4M | — |
| Q4 25 | $1.7M | $-2.1M | ||
| Q3 25 | $-4.9M | — | ||
| Q2 25 | $2.1M | $-14.9M | ||
| Q1 25 | $1.0M | $29.0M | ||
| Q4 24 | $2.5M | — | ||
| Q3 24 | $6.5M | — | ||
| Q2 24 | $7.3M | — | ||
| Q1 24 | $6.9M | — |
| Q4 25 | 7.6% | -15.3% | ||
| Q3 25 | -18.1% | — | ||
| Q2 25 | 9.1% | -184.0% | ||
| Q1 25 | 5.0% | 988.3% | ||
| Q4 24 | 10.2% | — | ||
| Q3 24 | 21.7% | — | ||
| Q2 24 | 28.5% | — | ||
| Q1 24 | 28.1% | — |
| Q4 25 | 0.1% | 0.7% | ||
| Q3 25 | 0.4% | 0.0% | ||
| Q2 25 | 0.0% | 5.0% | ||
| Q1 25 | 0.1% | 0.8% | ||
| Q4 24 | 3.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 2.0% | — |
| Q4 25 | — | -0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BGSF
| Contract Field Talent | $21.4M | 97% |
| Other | $595.0K | 3% |
XLO
Segment breakdown not available.
